15

20

## **CLAIMS**

What is claimed is:

1. A compound, including enantiomers, stereoisomers, rotomers and tautomers of said compound, and pharmaceutically acceptable salts, solvates or derivatives thereof, with said compound having the general structure shown in Formula I:

## Formula I

or a pharmaceutically acceptable derivative thereof, where X is:  $COCH(R^4)NHCO-CH(R^5)NHCOCH(R^6)NHCOR^n$  or  $COCH(R^4)NHCOCH(R^5)NHCOCH(R^6)-NHSO_2R^{20}$ ;

U<sup>1</sup> is a nitrogen atom and U is -CH-;

Z is: NH-CH( $R^{1'}$ )CONHCH( $R^{2'}$ )CONHCH( $R^{3'}$ )CONHCH( $R^{4'}$ )CONHCH( $R^{5'}$ )CORc;  $R^1$ ,  $R^2$ ,  $R^{22}$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^n$ ,  $R^{2'}$ ,  $R^{3'}$ ,  $R^{4'}$ ,  $R^{5'}$ ,  $R^{1'}$   $R^{20}$ , and  $R^c$  are selected from (a) and (b) as follows:

- (a) R<sup>1</sup> is selected from (i)-(v) as follows:
  - (i) C<sub>1-2</sub> alkyl substituted with Q;
  - (ii)  $C_{3-10}$  alkyl that is unsubstituted or substituted with Q;
  - (iii) cycloalkyl that is unsubstituted or substituted with Q;
  - (iv) alkenyl that is unsubstituted or substituted with Q; or
  - (v) alkynyl that is unsubstituted or substituted with Q;

R<sup>2</sup> and R<sup>22</sup> are selected from (i) or (ii) as follows:

(i) R<sup>2</sup> and R<sup>22</sup> together form alkylene, alkenylene, thiaalkylene, thiaalkenylene, alkylenethiaalkylene,

alkyleneazaalkylene, arylene, alkylenearylene or dialkylenearylene; or

(ii) R<sup>2</sup> and R<sup>22</sup> are each independently selected from H, alkyl, cycloalkyl, aralkyl and heteroaralkyl;

R<sup>3</sup> is selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl;

R<sup>4</sup> is alkyl, cycloalkyl, heteroaralkyl or aralkyl;

R<sup>5</sup> is alkyl or cycloalkyl;

R<sup>6</sup> is alkyl or cycloalkyl;

R<sup>n</sup> is alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, aralkenyl, aralkynyl, aryloxy, aralkoxy, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, heteroaryloxy, heteroaralkoxy or NR<sup>30</sup>R<sup>31</sup>;

R<sup>30</sup> and R<sup>31</sup> are each independently selected from the group consisting of H, alkyl, aryl, heteroaryl, aralkyl and heteroaralkyl;

R<sup>2'</sup> is H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl;

R<sup>3'</sup> is selected from the group consisting of alkyl, cycloalkyl, aralkyl and heteroaralkyl;

R4 is aralkyl or heteroaralkyl;

R<sup>5'</sup> is alkyl or cycloalkyl;

R<sup>1'</sup> is selected from H, alkyl, cycloalkyl, aralkyl and heteroaralkyl;

R<sup>20</sup> is alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl or heteroaralkynyl;

R<sup>c</sup> is selected from amino, hydroxy, alkoxy, cycloalkoxy, alkylamino, alkenyloxy, alkenylamino, aryloxy, heteroaryloxy, arylamino, heteroarylamino, aralkoxy, heteroaralkoxy, aralkylamino and heteroaralkylamino;

Q is halide, pseudohalide, hydroxy, nitrile, formyl, mercapto, alkyl, haloalkyl, polyhaloalkyl, alkenyl containing 1 double bond, alkynyl containing 1 triple bond, cycloalkyl, cycloalkylalkyl, alkylidene, alkylcarbonyl, alkoxy, perfluoroalkoxy, alkylcarbonyloxy or alkylthio; and

5

10

20

15

25

unsubstituted or substituted with one or more substituents each

R<sup>2</sup>, R<sup>22</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>n</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>1</sup>, R<sup>20</sup>, and R<sup>c</sup> are

5

10

15

20

25

independently selected from Q<sup>1</sup>, where Q<sup>1</sup> is halide, pseudohalide, hydroxy, oxo, thia, nitrile, nitro, formyl, mercapto, hydroxycarbonyl, hydroxycarbonylalkyl, alkyl, haloalkyl, polyhaloalkyl, aminoalkyl, diaminoalkyl, alkenyl containing 1 to 2 double bonds, alkynyl containing 1 to 2 triple bonds, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, aralkenyl, aralkynyl, heteroarylalkyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, triarylsilyl, alkylidene, arylalkylidene, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, aryloxycarbonyl, aryloxycarbonylalkyl, aralkoxycarbonyl, aralkoxycarbonylalkyl, arylcarbonylalkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, diarylaminocarbonyl, arylalkylaminocarbonyl, alkoxy, aryloxy, perfluoroalkoxy, alkenyloxy, alkynyloxy, aralkoxy, alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, aralkoxycarbonyloxy, ureido, alkylureido, arylureido, amino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylaminoalkyl, diarylaminoalkyl, alkylarylaminoalkyl, alkylamino, dialkylamino, arylamino, diarylamino, alkylarylamino, alkylcarbonylamino, alkoxycarbonylamino, aralkoxycarbonylamino, arylcarbonylamino, arylcarbonylaminoalkyl, aryloxycarbonylaminoalkyl, aryloxyarylcarbonylamino, aryloxycarbonylamino, alkylsulfonylamino, arylsulfonylamino, azido, dialkylphosphonyl, alkylarylphosphonyl, diarylphosphonyl, alkylthio, arylthio, perfluoroalkylthio, hydroxycarbonylalkylthio, thiocyano, isothiocyano, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylaminosulfonyl, diarylaminosulfonyl or alkylarylaminosulfonyl; and the aryl and heteroaryl groups of Q1 are unsubstituted or substituted with one or more substituents each independently selected from Q<sup>2</sup>, where

Q<sup>2</sup> is alkyl, halide, pseudohalide, alkoxy, aryloxy or alkylenedioxy; or

20

5

- R<sup>1</sup> and R<sup>3</sup>, and/or R<sup>2</sup> and R<sup>4</sup>, and/or R<sup>3</sup> and R<sup>5</sup>, and/or R<sup>4</sup> and R<sup>6</sup>, (b) and/or R<sup>1</sup> and R<sup>2</sup>, and/or R<sup>1</sup> and R<sup>3</sup>, and/or R<sup>2</sup> and R<sup>4</sup>, and/or R<sup>3</sup> and R<sup>5</sup>, and/or R<sup>2</sup> and R<sup>1</sup>, and/or R<sup>1</sup> and R<sup>1</sup> together form alkylene, alkenylene, alkylenearylene, dialkylenearylene, alkylene-OC(O)-alkylene, alkylene-NHC(O)-alkylene, alkylene-O-alkylene, alkylene-NHC(O)-alkylene-NHC(O)alkylene, alkylene-C(O)NH-alkylene-NHC(O)-alkylene, alkylene-NHC(O)alkylene-C(O)NH-alkylene, alkylene-S(O)<sub>m</sub>-S(O)<sub>m</sub>-alkylene or alkylene-S(O)<sub>m</sub>-alkylene where m is 0-2, and the alkylene and arylene portions are unsubstituted or substituted with Q1; and the others are chosen as in (a).
- The compound of claim 1, wherein Z is: 2. NH-CH(R<sup>1'</sup>)CONHCH(R<sup>2'</sup>)CONHCH(R<sup>3'</sup>)CONHCH(R<sup>4'</sup>)CONHCH(R<sup>5'</sup>)COR<sup>c</sup>,: and R<sup>1</sup> is selected from (i)-(iv) as follows:
  - (i) C<sub>1-2</sub> alkyl that is substituted with Q;
  - C<sub>3-10</sub> alkyl that is unsubstituted or substituted with Q; (ii)
  - alkenyl that is unsubstituted or substituted with Q; or (iii)
  - alkynyl that is unsubstituted or substituted with Q; (iv)

R<sup>2</sup> and R<sup>22</sup> are selected from (i) or (ii) as follows:

- R<sup>2</sup> and R<sup>22</sup> together form alkylene, thiaalkylene, or (i) dialkylenearylene; or
- R<sup>2</sup> and R<sup>22</sup> are each independently selected from H, alkyl and (ii) aralkyl;

R<sup>3</sup> is selected from the group consisting of alkyl, cycloalkyl, aryl and aralkyl;

R<sup>4</sup> is alkyl, heteroaralkyl or aralkyl;

R<sup>5</sup> is alkyl;

R<sup>6</sup> is alkyl; 25

R<sup>n</sup> is alkyl, hydroxycarbonylalkyl, alkoxy, heteroaryl, aryl or aralkyl;

R<sup>2'</sup> is H, alkyl, cycloalkyl, aryl or aralkyl;

R<sup>3'</sup> is selected from the group consisting of alkyl and heteroaralkyl:

R4 is aralkvl:

R<sup>5'</sup> is alkyl; 30

15

20

R<sup>1'</sup> is selected from H, alkyl and aralkyl;

R<sup>20</sup> is alkyl, aryl, aralkyl or aralkenyl;

R<sup>c</sup> is selected from amino, hydroxy, alkoxy, alkenyloxy, alkylamino, alkenylamino and aralkylamino;

Q is halide, pseudohalide, hydroxy, nitrile, formyl, mercapto, alkyl, haloalkyl, polyhaloalkyl, alkenyl containing 1 double bond, alkynyl containing 1 triple bond, cycloalkyl, cycloalkylalkyl, alkylidene, alkylcarbonyl, alkoxy, perfluoroalkoxy, alkylcarbonyloxy or alkylthio; and

alkylcarbonyloxy or alkylthio; and R<sup>2</sup>, R<sup>22</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>n</sup>, R<sup>2′</sup>, R<sup>3′</sup>, R<sup>4′</sup>, R<sup>5′</sup>, R<sup>1′</sup>, R<sup>20</sup>, and R<sup>c</sup> are unsubstituted or substituted with one or more substituents each independently selected from Q<sup>1</sup>, where Q<sup>1</sup> is halide, pseudohalide, hydroxy, oxo, thia, nitrile, nitro, formyl, mercapto, hydroxycarbonyl, hydroxycarbonylalkyl, alkyl, haloalkyl, polyhaloalkyl, aminoalkyl, diaminoalkyl, alkenyl containing 1 to 2 double bonds, alkynyl containing 1 to 2 triple bonds, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, aralkenyl, aralkynyl, heteroarylalkyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, triarylsilyl, alkylidene, arylalkylidene, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, aralkoxycarbonyl, aralkoxycarbonylalkyl, arylcarbonylalkyl, aryloxycarbonylalkyl, arylcarbonyl, dialkylaminocarbonyl, alkoxy, aryloxy, perfluoroalkoxy, diarylaminocarbonyl, arylalkylaminocarbonyl, alkoxy, aryloxy, perfluoroalkoxy,

alkenyloxy, alkynyloxy, aralkoxy, alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, aralkoxycarbonyloxy, ureido, alkylureido, arylureido, amino, aminoalkyl, alkylaminoalkyl, diarylaminoalkyl, alkylarylaminoalkyl,

alkylamino, dialkylamino, arylamino, diarylamino, alkylarylamino, alkylcarbonylamino, alkoxycarbonylamino, aralkoxycarbonylamino, arylcarbonylamino, arylcarbonylaminoalkyl, aryloxycarbonylaminoalkyl, aryloxyarylcarbonylamino, aryloxycarbonylamino, alkylsulfonylamino, arylsulfonylamino, azido, dialkylphosphonyl, alkylarylphosphonyl,

diarylphosphonyl, alkylthio, arylthio, perfluoroalkylthio, hydroxycarbonylalkylthio,

10

15

20

thiocyano, isothiocyano, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylaminosulfonyl, diarylaminosulfonyl or alkylarylaminosulfonyl; and

the aryl and heteroaryl groups of Q<sup>1</sup> are unsubstituted or substituted with one or more substituents each independently selected from Q<sup>2</sup>, where Q<sup>2</sup> is alkyl, halide, pseudohalide, alkoxy, aryloxy or alkylenedioxy.

3. The compound of claim 2, wherein:

 $R^1$  is  $C_{3-10}$  alkyl, or is alkenyl or alkynyl, and is unsubstituted or substituted with Q;

R<sup>2</sup> and R<sup>22</sup> are selected from (i) or (ii) as follows:

- (i) R<sup>2</sup> and R<sup>22</sup> together form propylene, butylene or 1,2-dimethylenephenylene, where the butylene and 1,2-dimethylenephenylene groups are unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxy-carbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxy-carbonylamino, hydroxycarbonylmethyl, hydroxycarbonylmethoxy, 2-propen-1-yl, N-(4-methoxyphenyl)ureido, 3-phenoxybenzoylamino, 4-methoxyphenylmethyl, 9-fluorenylmethoxycarbonylamino, benzyl, 4-methoxybenzoylamino, benzoylamino, 3,4-methylenedioxybenzoylamino, 4-fluorobenzoylamino, phenylsulfonylamino, 4-phenoxybenzoylamino or amino; or
- $\label{eq:coom} \mbox{(ii)} \qquad \mbox{$R^2$ is selected from $CH_2SO_2$Me, $CH_2SCH_2$COOH,} $$$ $CH_2CH_2COOH and $CH_2$SMe; and $R^{22}$ is $H$; and $$$$ $R^3$ is i-Pr, cyclohexyl or 1-methyl-1-propyl.$
- 4. The compound of claim 2, wherein:

 $R^1$  is  $C_{3-10}$  alkyl, or is alkenyl or alkynyl, and is unsubstituted or substituted with Q:

 $R^2$  and  $R^{22}$  are selected from (i) or (ii) as follows:

30

10

15

20

25

- (i) R² and R²² together form propylene or 1,2-dimethylenephenylene, where the 1,2-dimethylenephenylene group is unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxy-carbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxy-carbonylamino, hydroxycarbonylmethyl or hydroxycarbonylmethoxy; or
- (ii)  $R^2$  is selected from  $CH_2SO_2Me$  and  $CH_2SCH_2COOH$ ; and  $R^{22}$  is H; and  $R^3$  is i-Pr. cyclohexyl or 1-methyl-1-propyl.
- 5. The compound of claim 2, wherein:

R<sup>1</sup> is unsubstituted C<sub>3-10</sub> alkyl;

R<sup>2</sup> and R<sup>22</sup> together form propylene or 1,2-dimethylenephenylene, where the 1,2-dimethylenephenylene group is unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenyl-ureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenyl-methoxycarbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxycarbonylamino, hydroxycarbonylmethyl or hydroxycarbonylmethoxy; and R<sup>3</sup> is i-Pr, cyclohexyl or 1-methyl-1-propyl.

- 6. The compound of claim 6, wherein R<sup>1</sup> is n-Pr; and R<sup>2</sup> and R<sup>22</sup> together form unsubstituted propylene.
- 7. The compound of claim 1, wherein X is: COCH(R<sup>4</sup>)NHCOCH(R<sup>5</sup>)NHCOCH(R<sup>6</sup>)NHCOR<sup>n</sup>.
  - 8. The compound of claim 7, wherein:

 $R^1$  is  $C_{3-10}$  alkyl, or is alkenyl or alkynyl, and is unsubstituted or substituted with Q;

R<sup>2</sup> and R<sup>22</sup> are selected from (i) or (ii) as follows:

10

15

20

- (i) R² and R²² together form propylene, butylene or 1,2-dimethylenephenylene, where the butylene and 1,2-dimethylenephenylene groups are unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxy-carbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxy-carbonylamino, hydroxycarbonylmethyl, hydroxycarbonylmethoxy, 2-propen-1-yl, N-(4-methoxyphenyl)ureido, 3-phenoxybenzoylamino, 4-methoxyphenylmethyl, 9-fluorenylmethoxycarbonylamino, benzyl, 4-methoxybenzoylamino, benzoylamino, 3,4-methylenedioxybenzoylamino, 4-fluorobenzoylamino, phenylsulfonylamino, 4-phenoxybenzoylamino or amino; or
- (ii) R<sup>2</sup> is selected from CH<sub>2</sub>SO<sub>2</sub>Me, CH<sub>2</sub>SCH<sub>2</sub>COOH, CH<sub>2</sub>CH<sub>2</sub>COOH and CH<sub>2</sub>SMe; and R<sup>22</sup> is H; and R<sup>3</sup> is i-Pr, cyclohexyl or 1-methyl-1-propyl.
- 9. The compound of claim 7, wherein:

  R¹ is C₃-10 alkyl, or is alkenyl or alkynyl, and is unsubstituted or substituted with Q:

R<sup>2</sup> and R<sup>22</sup> are selected from (i) or (ii) as follows:

- (i) R² and R²² together form propylene or 1,2-dimethylenephenylene, where the 1,2-dimethylenephenylene group is unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxy-carbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxy-carbonylamino, hydroxycarbonylmethyl or hydroxycarbonylmethoxy; or
- (ii) R<sup>2</sup> is selected from CH<sub>2</sub>SO<sub>2</sub>Me and CH<sub>2</sub>SCH<sub>2</sub>COOH; and R<sup>22</sup> is H; and

30

25

30

```
R<sup>3</sup> is i-Pr, cyclohexyl or 1-methyl-1-propyl.
```

The compound of claim 9, wherein: 10.

R<sup>1</sup> is unsubstituted C<sub>3-10</sub> alkyl;

R<sup>2</sup> and R<sup>22</sup> together form propylene or 1,2-dimethylenephenylene, where the 1,2-dimethylenephenylene group is unsubstituted and the propylene group is 5 unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxycarbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxycarbonylamino, hydroxycarbonylmethyl or hydroxycarbonylmethoxy; and 10 R<sup>3</sup> is i-Pr, cyclohexyl or 1-methyl-1-propyl.

- The compound of claim 10, wherein R<sup>1</sup> is n-Pr; and R<sup>2</sup> and R<sup>22</sup> together 11. form unsubstituted propylene.
- 12. The compound of claim 7, wherein:

R<sup>4</sup> is alkyl, heteroaralkyl or aralkyl;

R<sup>5</sup> is alkyl;

R<sup>6</sup> is alkyl: and

R<sup>n</sup> is alkyl, alkoxy, heteroaryl, aryl or aralkyl.

13. The compound of claim 7, wherein:

R⁴ is i-Pr:

R<sup>5</sup> and R<sup>6</sup> are CH<sub>2</sub>CH<sub>2</sub>COOH; and

R<sup>n</sup> is methyl.

14. The compound of claim 2, wherein:

R<sup>2'</sup> is CH<sub>2</sub>CH<sub>2</sub>SMe, C(OH)Me, CH<sub>2</sub>CH<sub>2</sub>S(O)Me, phenyl or CH<sub>2</sub>C(O)NH<sub>2</sub>;

R<sup>3'</sup> is hydroxymethyl, hydroxycarbonylmethyl or 4-imidazolylmethyl;

R<sup>4'</sup> is 4-hydroxyphenylmethyl;

R<sup>5'</sup> is hydroxymethyl; and

R<sup>1'</sup> is H.

15. The compound of claim 6, wherein:

R<sup>2'</sup> is H, alkyl or aryl;

```
R<sup>3'</sup> is alkyl or heteroaralkyl;
```

R4' is aralkyl;

R<sup>5'</sup> is alkyl; and

R<sup>1'</sup> is H, alkyl or aralkyl.

5 16. The compound of claim 6, wherein:

R<sup>2'</sup> is CH<sub>2</sub>CH<sub>2</sub>SMe, C(OH)Me, CH<sub>2</sub>CH<sub>2</sub>S(O)Me, phenyl or CH<sub>2</sub>C(O)NH<sub>2</sub>;

R<sup>3'</sup> is hydroxymethyl, hydroxycarbonylmethyl or 4-imidazolylmethyl;

R4' is 4-hydroxyphenylmethyl;

R<sup>5'</sup> is hydroxymethyl; and

R<sup>1'</sup> is H.

17. The compound of claim 1, wherein the compound is selected from the group consisting of:

AcEEVVPnV-(CO)-GMSYS-Am

AcEEVVPnV-CO-GMdSYS-Am

15 AcEEVVPnV-CO-GMdHYS-Am

AcEEVVPnV-CO-GMdDYS-Am

AcEEVVPnV-CO-GdMSYS-Am

AcEEVVPnV-CO-GdMdSYS-Am

AcEEVVPnV-CO-GdMHYS-Am

20 AcEEVVPnV-CO-GdMDYS-Am

AcEEVVPnV-CO-GdMdDYS-Am

AcEEVVPnV-CO-GGSYS-Am

AcEEVVPnV-CO-GGHYS-Am

AcEEVVPnV-CO-GGdHYS-Am

25 AcEEVVPnV-CO-GGDYS-Am

AcEEVVPnV-CO-GGdDYS-Am

AcEEVVPnV-CO-GQSYS-Am

AcEEVVPnV-CO-GQdSYS-Am

AcEEVVPnV-CO-GQdHYS-Am

30 AcEEVVPnV-CO-GQdDYS-Am

20

25

30

AcEEVVPnV-CO-GdQSYS-Am AcEEVVPnV-CO-GdQdSYS-Am AcEEVVPnV-CO-GdQHYS-Am AcEEVVPnV-CO-GdQDYS-Am AcEEVVPnV-CO-GdQdDYS-Am AcEEVVPnV-CO-GTSYS-Am AcEEVVPnV-CO-GTdSYS-Am AcEEVVPnV-CO-GTHYS-Am AcEEVVPnV-CO-GTDYS-Am AcEEVVPnV-CO-GTdDYS-Am AcEEVVPnV-CO-GSdSYS-Am AcEEVVPnV-CO-GSdHYS-Am AcEEVVPnV-CO-GSdDYS-Am AcEEVVPnV-CO-GdSSYS-Am AcEEVVPnV-CO-GdSdSYS-Am AcEEVVPnV-CO-GdSHYS-Am AcEEVVPnV-CO-GdSdHYS-Am AcEEVVPnV-CO-GdSDYS-Am AcEEVVPnV-CO-GdSdDYS-Am AcEEVVPnV-CO-GM(O)HYS-Am AcEEVVPnV-(CO)-GdM(O)SYS-Am AcEEVVPnV-CO-GdM(O)dHYS-Am AcEEVVPnV-CO-GdM(O)DYS-Am AcEEVVPnV-CO-GdM(O)dDYS-Am Ac-EEVVP-V-(CO)-GMSYS-Am Ac-EEVVP-L-(CO)-GMSYS-Am Ac-EEVVP-nL-(CO)-GMSYS-Am Ac-EEVVP-Abu-(CO)-GMSYS-Am

Ac-EEVVP-(s,s)alloT-(CO)-GMSYS-Am Ac-EEVVP-G(propynyl)-(CO)-GMSYS-Am

18. The compound of claim 1, wherein the compound is selected from the group consisting of:

AcEEVVPnV-CO-GdMDYS-Am

AcEEVVPnV-CO-GdMdDYS-Am

AcEEVVPnV-CO-GGSYS-Am

AcEEVVPnV-CO-GGHYS-Am

AcEEVVPnV-CO-GGDYS-Am

AcEEVVPnV-CO-GGdDYS-Am

AcEEVVPnV-CO-GQSYS-Am

AcEEVVPnV-CO-GQdSYS-Am

AcEEVVPnV-CO-GQdHYS-Am

AcEEVVPnV-CO-GQdDYS-Am

AcEEVVPnV-CO-GdQSYS-Am

AcEEVVPnV-CO-GdQdSYS-Am

AcEEVVPnV-CO-GdQHYS-Am

AcEEVVPnV-CO-GdQDYS-Am

AcEEVVPnV-CO-GdQdDYS-Am

AcEEVVPnV-CO-GTSYS-Am

AcEEVVPnV-CO-GTdSYS-Am

20 AcEEVVPnV-CO-GTHYS-Am

AcEEVVPnV-CO-GTDYS-Am

AcEEVVPnV-CO-GTdDYS-Am

AcEEVVPnV-CO-GSdSYS-Am

AcEEVVPnV-CO-GSdHYS-Am

25 AcEEVVPnV-CO-GSdDYS-Am

AcEEVVPnV-CO-GdSSYS-Am

AcEEVVPnV-CO-GdSdSYS-Am

AcEEVVPnV-CO-GdSHYS-Am

AcEEVVPnV-CO-GdSdHYS-Am

30 AcEEVVPnV-CO-GdSDYS-Am

15

AcEEVVPnV-CO-GdSdDYS-Am

AcEEVVPnV-CO-GM(O)HYS-Am

AcEEVVPnV-(CO)-GdM(O)SYS-Am

AcEEVVPnV-CO-GdM(O)DYS-Am

5 AcEEVVPnV-CO-GdM(O)dDYS-Am

Ac-EEVVP-(s,s)alloT-(CO)-GMSYS-Am

Ac-EEVVP-G(propynyl)-(CO)-GMSYS-Am

- 19. A pharmaceutical composition comprising as an active ingredient a compound of claim 1.
- 20. The pharmaceutical composition of claim 19 for use in treating disorders associated with Hepatitis C virus.
- 21. The pharmaceutical composition of claim 19 additionally comprising a pharmaceutically acceptable carrier.
- 22. The pharmaceutical composition of claim 21, additionally containing an antiviral agent.
- 23. The pharmaceutical composition of claim 22, still additionally containing an interferon.
- 24. The pharmaceutical composition of claim 23, wherein said antiviral agent is ribavirin and said interferon is  $\alpha$ -interferon.
- 25. A method of treating disorders associated with the HCV protease, said method comprising administering to a patient in need of such treatment a pharmaceutical composition which composition comprises therapeutically effective amounts of a compound of claim 1.
  - 26. The method of claim 25, wherein said administration is subcutaneous.
- 25 27. The use of a compound of claim 1 for the manufacture of a medicament to treat disorders associated with the HCV protease.
  - 28. A method of preparing a pharmaceutical composition for treating disorders associated with the HCV protease, said method comprising bringing into intimate contact a compound of claim 1 and a pharmaceutically acceptable carrier.

- 29. A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the group of compounds in claim 17.
- 30. A pharmaceutical composition for treating disorders associated with the HCV protease, said composition comprising therapeutically effective amount of one or more compounds in claim 17 and a pharmaceutically acceptable carrier.